Keyword Index to Volume 12

Size: px

Start display at page:

Download "Keyword Index to Volume 12"

Noreen Richards
5 years ago
Views:

1 Journal of Clinical Lipidology (2018) 12, e7 e12 Keyword Index to Volume 12 A ABCA1, 116 ABCA1 transporter, 1374 ABCG5, 1164 ABCG5/G8 genes, 152 ABCG8, 246, 1164 Abdominal pain, 898 ABO, 383 ACC, 826 Acipimox, 1260 ACTIVE/ADIPOSE, 481 Acute coronary syndrome, 685 Acute pancreatitis, 305, 898, 1234, 1371 Adherence, 1008 Adolescent, 403 Adrenocortical carcinoma, 826 Adverse reactions, 643 Age, 748 AIM-HIGH trial, 1413 Albumin, 1539 Alirocumab, 162, 390, 662, 835, 1463 ALL-BFM 2000, 1260 All-cause death, 1404 Allele frequency, 145 Angiopoietin-like 4, 56 Angiopoietin-like protein 4, 583 Angiopoietin-like protein 8, 331 ANGPTL4, 583, 773 Ankle-brachial index, 1039 Anti-LPL autoantibody, 883 Antioxidant, 1539 Antisense oligonucleotides, 122, 702 Aortic stenosis, 1313 APO C-III, 254 APOA1, 116 APOA5, 1146 APOB, 390, 1383 apoc-iii, 1493 apoe polymorphisms, 702 Apolipoprotein, 254, 588 Apolipoprotein A-1, 822 Apolipoprotein A-I, 498, 511, 1086 Apolipoprotein B, 44, 481 Apolipoprotein B-100, 230, 300 Apolipoprotein C-III, 1086 Apolipoprotein C2, 481 Apolipoprotein CIII, 801, 810 Apolipoprotein E, 89, 1086 Arabs, 685 ARH1, 145 ARHGEF10, 311 Arrhythmia, 1298 Arterial stiffness, 397 Arteriosclerosis, 511 Assay, 1313 Atherogenesis, 849 Atherogenic dyslipidemia, 1267 Atherosclerosis, 116, 137, 338, 615, 878, 1267, 1513 Atherosclerotic burden, 597 Atherosclerotic cardiovascular disease, 574, 674, 999, 1179 Atherosclerotic cardiovascular disease (ASCVD), 1008 Atherosclerotic plaque, 615 Atherothrombosis, 1335 Atherothrombotic disease, 1358 Atorvastatin, 44, 130, 801 ATP-binding cassette transporter A1, 849 Autoantibody, 888 Autoimmune hyperlipidemia, 883 Autosomal recessive hypercholesterolemia, 145 B Bariatric surgery, 193, 1027, 1502 Betatrophin, 331 Bile acid, 1170 Blood group, 383 Blood pressure, 70 Blood pressure reduction, 1113 Body mass index, 428 Bone marrow, 33 Brachial artery vasoreactivity test, 669 Brain, 1123 Breastfeeding, 437 Brown adipose tissue, 56 Burden of illness, 898 C CAD, 110 Calcific aortic stenosis, 1335 Cancer, 1179 Candidate genes, 1482 Capecitabine, 1371 Cardiometabolic diseases, 1027 Cardiometabolic risk factors, 1113 Cardiomyopathy, 1513 cardioprotection, 110 Cardiovascular, 481, 626, 1061, 1346 Cardiovascular abnormality, 685 Cardiovascular disease, 16, 348, 367, 383, 409, 597, 674, 801, 966, 988, 1072, 1313, 1404, /$ - see front matter Ó 2017 National Lipid Association. All rights reserved.

2 e8 Journal of Clinical Lipidology, Vol 12, No 6, December 2018 Cardiovascular diseases, 403, 1141 Cardiovascular events, 122 Cardiovascular outcome, 277 Cardiovascular outcomes, 356, 835 Cardiovascular risk, 447, 999, 1217, 1335, 1445, 1453 Cardiovascular risk factors, 464 Carotid atherosclerosis, 1039 Cataract, 728 Causative mutation, 1483 Cerebrotendinous xanthomatosis, 1169 CETP, 130, 784 CETP inhibitor, 972 CHD risk reduction, 1413 Chenodeoxycholic acid, 1169 Child, 236 Childhood acute lymphoblastic leukemia, 1260 Childhood obesity, 981 Childhood stroke, 1335 Children, 211, 375, 748, 1208 Cholestanol, 1169 Cholesterol, 356, 583, 702, 741, 748, 822, 1123, 1390 Cholesterol bioavailability, 849 Cholesterol biosynthesis, 1169 Cholesterol efflux, 1072, 1374 Cholesterol efflux capacity, 193, 1086, 1267 Cholesterol levels, 1208 Cholesterol lowering, 857 Cholesterol-lowering treatment, 1123 Cholesterol overloaded, 89 Cholesteryl ester storage disease, 604 Chylomicronemia, 240, 898, 908, 1234 Chylomicronemia syndrome, 1244 Clinical effectiveness, 1113 Clinical management, 254 Clinical pharmacist, 999 Clinical studies, 1358 Clinical trial, 417, 1190 Clinical trials, 857 Cohort, 137 Cohort study, 1179 Cold exposure, 56 Community-based cohort study, 89 Confounding, 1358 CoQ10, 417 Coronary artery calcium, 615 Coronary artery calcium score, 597 Coronary artery disease, 246, 455, 878, 937, 949, 966, 1019, 1141, 1493 Coronary atherosclerotic plaque, 1133 Coronary CTA, 949 Coronary heart disease, 662, 1358 Coronary heart disease risk, 300 Corticosteroid therapy, 305 Cost savings, 1113 CREB3L3, 1146 CYP27A1 gene, 1169 Cytokines, 1374 D 2D-1H-NMR, 211 Desaturase, 1280 DHA, 937, 1047 Diabetes, 331, 447, 685 Diabetes mellitus, 130, 1371 Diabetes mellitus type 1, 734 Diagnosis, 1383 Dialysis, 1513 Dietary fats, 574 Dietary recommendations, 908 DNA sequencing, 230 Docosahexaenoic acid, 718, 937 Dose adjustment, 1463 Downhill walking, 1305 Dutch Lipid Clinic Network score, 1453 Dynamic cohort study, 185 Dyslipidaemia, 1217 Dyslipidemia, 99, 173, 367, 417, 447, 464, 488, 604, 626, 981, 988, 1141, 1208, 1244, 1421, 1471 Dyslipidemia management, 1113 Dyslipidemias, 403 Dyslipoproteinemia, 1383 E Early lipid changes, 219 Efficacy, 277 Eicosapentaenoic acid, 718, 937 Endothelial cells, 1532 Endothelial dysfunction, 1523 Endothelial function, 669 Enzyme replacement therapy, 604 EPA, 937 Epidemiology, 137, 403, 674, 718, 1358 ER niacin, 810 Erectile dysfunction, 1039 Eruptive xanthoma, 1146 Essential polyunsaturated fatty acids, 1047 Estrogen, 1146 Ethnicity, 1217 Event reduction, 958 Evolocumab, 669, 826, 835, 1199 Exercise, 937 Exome sequencing, 110 Expanded use, 662 Extended follow-up, 1413 Extended release niacin, 741, 1413 Extreme hypertriglyceridemia, 305 Extremely restrictive low-fat diet, 1234 Ezetimibe, 292, 741 Ezetimibe therapy, 152, 1133 F 18 FDG PET/CT, 33 FADS1, 1280 Falls, 652 Familial chylomicronemia syndrome, 305, 506, 898, 920, 1234, 1482 Familial chylomicronemia syndrome (FCS), 240, 908 Familial dyslipidemias, 33 Familial hypercholesterolemia, 25, 211, 230, 236, 375, 383, 397, 403, 409, 693, 748, 767, 863, 868, 949, 958, 966, 972, 1164, 1199, 1208, 1436, 1445, 1452, 1463

3 Journal of Clinical Lipidology, Vol 12, No 6, December 2018 Fatty acid desaturases, 311 Fatty acids, 1404 Fatty liver, 173 Fatty liver disease, 1390 Ferritin, 1190 FGF23, 767 Fibrates, 173 Fibrinogen, 1539 Fish oil, 937 Flaxseed oil, 70 Functional assay, 1253 Functional variant, 1280 G Gene mutation, 230, 1146 Gene polymorphism, 1280 Genetic, 1244 Genetic epidemiology, 1280 Genetic risk stratification, 338 Genetic screening, 1253 Genetic testing, 375 Genetic variation, 920 Genetics, 116, 122, 878, 920, 1421, 1436 Genome, 511 Genome-wide association study, 311 Gensini, 1019 Gestational hypertension, 428 GLP-1R agonist, 62 Glucose disposal rate, 734 GlycA, 348 Glycated apolipoprotein B, 44 Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein-1, 203 GPIHBP1, 506 Guideline, 1008 Guidelines, 1346 GWAS, 266 H HALP, 110 Haplotype, 338 HbA1c, 62 HCV, 756 HDL, 99, 116, 810, 822, 1072, 1532 HDL biogenesis, 849 HDL-C, 110 HDL-C treatment, 1413 HDL cholesterol, 878, 1061 Health, 1346 Health care evaluation, 1225 Health-related quality of life, 1225 Healthy lifestyle, 615 Heart failure, 1404 HELIUS study, 1217 Hematopoietic stem cell transplantation, 464 Heme, 1532 Hemodialysis, 488 Hemolysis, 1532 Hemopexin, 1532 Hemorrhagic stroke, 1179 Heterozygous carriers, 145 Heterozygous familial, 872 Heterozygous familial hypercholesterolemia, 662 High-density lipoprotein, 44, 89, 488, 741, 784, 1471 High-density lipoprotein cholesterol, 356, 674, 1374 High-density lipoprotein (HDL), 1539 High-density lipoprotein subfractions, 1290 High-density lipoproteins, 588, 1086, 1267 High-intensity statin therapy, 999 HIV infection, 988 HMG-CoA reductase inhibitors (statins), 78 Homocysteine, 173 Homozygote state, 693 Hospitalization, 652 HPLC/GFC, 1157 Human adipose tissue, 773 Hyperalpha, 110 Hypercholesterolemia, 145,152, 162, 246, 390, 685, 826, 872, 1019, 1141, 1367, 1523 Hyperchylomicronemia, 243, 254, 883 Hyperinsulinemic-euglycemic clamp, 734 Hyperlipidemia, 243, 331, 643 Hyperlipoproteinemia, 898, 908, 1234 Hyperthyroidism, 1367 Hypertriglyceridemia, 240, 321, 331, 898, 908, 920, 928, 1146, 1190, 1234, 1244, 1260 Hyperuricemia, 185 Hypoalphalipoproteinemia, 1374 Hypothyroidism, 1367 I Ideal, 1346 IDOL, 211 Immunoassay, 300 Immunoglobulin G, 1539 In vitro fertilization, 1146 Incident coronary heart disease, 89 Infection, 481 Infective endocarditis, 498 Inflammation, 338, 810, 1047 Inflammatory cytokines, 44 Insulin resistance, 417, 734, 810, 1290, 1298, 1421 Interleukin-6, 810 Intima-media thickness, 1039 Intravascular ultrasound, 1133 Iron overload, 1190 Isoforms, 122 K K-877, 173, 1267 Kidney disease, 1061 L L-asparaginase therapy, 305 Lathosterol, 756 LCAT, 1157 LCAT deficiency, 1151 LDL, 99, 211, 481, 583, 810, 863, 1532 LDL-C, 162, 437, 662, 1199, 1463 e9

4 e10 Journal of Clinical Lipidology, Vol 12, No 6, December 2018 LDL-C levels, 25 LDL cholesterol, 62, 152, 375, 626, 711, 728, 972, 999, 1027, 1039, 1523 LDL receptor, 868 LDLR, 211, 390 LDLR mutations, 693 LDLRAP1, 390 Lebanon, 1374 Lecithin-cholesterol acyltransferase, 888 Leptin, 1421 Lipase maturation factor-1 (LMF1), 1253 Lipemic serum, 243 Lipid, 488, 756 Lipid composition, 588 Lipid lowering, 162, 464 Lipid-lowering therapy, 292, 375, 409, 711 Lipid mediators, 1047 Lipid metabolism, 583, 773 Lipid peroxidation, 70, 1539 Lipid profile, 1217 Lipid screening, 1445 Lipid targets, 711 Lipid treatment guideline, 999 Lipidomics, 1502 Lipids, 428, 583, 588, 822 Lipodystrophy, 1421 Lipolysis, 920, 1245 Lipomatosis, 1421 Lipoprotein, 266, 888 Lipoprotein apheresis, 868, 1225 Lipoprotein lipase, 203, 240, 243, 254, 920 Lipoprotein lipase deficiency, 898, 908, 1234 Lipoprotein particle subclasses, 193 Lipoprotein particles, 348 Lipoprotein receptors, 849 Lipoprotein subfractions, 741 Lipoprotein X, 1151 Lipoprotein(a), 16, 122, 130, 597, 702, 1019, 1313, 1335, 1445 Lipoproteins, 99, 338, 428, 481, 1072, 1390 Liquid chromatography-tandem mass spectrometry, 756 Liver, 1390 Liver dysfunction, 173 Long term, 277 Long-term breastfeeding, 437 Long-term care, 652 Long-term survivors, 464 Lovastatin, 801 Low-density lipoprotein, 45, 702, 784, 1471 Low-density lipoprotein cholesterol, 230, 356, 397, 988, 1179, 1436, 1445 Low-density lipoprotein (LDL), 1539 Low-density lipoprotein receptor, 230 Low-density lipoproteins, 588 Low-fat diet, 908 Low-grade inflammation, 1290 Low HDL, 878 Low-LDL, 292 Low-LDL safety, 292 Lp-X, 1157 Lp8, 1157 Lp(a), 211 LPL, 773 LPL activity, 1253, 1483 LPL mass, 1483 Lymphocyte antigen 6, 203 Lysosomal acid lipase deficiency, 604 M Malaria, 822 Malignancy, 1061 Mass spectrometry, 1027, 1539 Maximally tolerated statin, 162 Medical nutrition therapy, 1113 Mendelian randomization, 137 Meta-analysis, 16, 277, 728 Metabolic follow-up, 219 Metabolic syndrome, 70, 447, 784, 810, 981, 1113, 1290, 1298 Metabolomics, 756, 1502 Microcirculation, 1523 Middle East, 685 mirna, 1280 Misdiagnosed, 236 Mitochondria, 1421 Mitofusin 2, 1421 Mitotane, 826 Mixed dyslipidemia, 784, 810 Molecular diagnosis, 1453 Monoclonal antibody, 203, 1199 Monounsaturated fat, 574 Mortality, 455, 488, 652, 674, 928, 1061 Multi-ethnic Study of Atherosclerosis, 300 Muscle, 1305 Muscle pain, 78 Muscle weakness, 78 Mutation, 511 Myalgia, 78 Myocardial infarction, 246, 928, 1493 N Natural history, 1234 Nephrotic syndrome, 888 Neurocognitive function, 1123 Neurologic abnormality, 1170 Neuropathy, 1421 New onset dyslipidemia, 219 Next-generation DNA sequencing, 920 NGS-based gene panel, 145 Non-alcoholic fatty liver disease, 1390 Non-HDL-C, 437 Non-high-density lipoprotein cholesterol, 321 Nonalcoholic fatty liver disease, 981 Normal values, 1208 Novel mutation c.-139delctccccctgc, 693 Novel rare genetic variant, 878 Nuclear magnetic resonance spectroscopy, 348 O u-oxidation, 756 Obesity, 25, 193, 447, 1502 ODYSSEY, 662 ODYSSEY phase 3, 162

5 Journal of Clinical Lipidology, Vol 12, No 6, December 2018 e11 Omega-3 carboxylic acids, 321 Omega-3 fatty acids, 718, 937, 1260, 1390 Open-label extension, 1463 Overweight, 25 Oxidation, 338 Q QTc interval, 1298 Quality of life, 898 Quantitative proteomics, 1027 P Painless thyroiditis, 1367 Palmitic acid, 455 Pancreas, 1390 Pancreatitis, 240, 506, 898, 908, 920, 928 Paraoxonase-1 (PON1), 193 Pathogenicity evaluation, 1253 PBC, 1157 PCSK9, 130, 162, 211, 826, 835, 868, 1027, 1039, 1123, 1199, 1436, 1463 PCSK9 antibodies, 728 PCSK9 inhibition, 958 PCSK9 inhibitor, 662, 972 PCSK9 inhibitors, 292, 669, 826, 1123, 1141 Pediatric, 25, 981, 1346 Pediatrics, 908, 1445 Pemafibrate, 173, 1267 Peripheral arterial disease, 711 PHACTR1, 966 Pharmacists, 367 Pharmacogenetics, 266 Phlebotomy, 1190 Phospholipids, 1502 Phosphorylation, 1027 Physical complaints, 1225 Physical function, 937 Pitavastatin, 784 Placebo-controlled, 162 Polygenic hypercholesterolemia, 1452 Polymorphism, 338 Polyunsaturated fat, 574 Polyunsaturated fatty acids, 311, 1280 Population study, 1208 Postprandial hyperlipidemia, 1267 Posttranslational modifications, 1027 PPARs, 1390 Practice guidelines, 367 Prebeta-1 HDL, 99 Predictors, 219, 643 Preeclampsia, 428 Pregnancy, 506, 1146, 1151 Premature atherosclerotic cardiovascular disease, 597 Premature coronary heart disease, 236 Prescription, 1008 Prevalence, 1471 Primary prevention, 1179 Primordial prevention, 1445 Prognosis, 498, 949 Proprotein convertase subtilisin kexin type 9, 702 Proprotein convertase subtilisin/kexin type 9, 230, 397 Prospective cohort study, 718 Proteinuria, 1151 PSCK9 antibody, 277 Psoriasis, 1047 Psychotropic drugs, 219 R R46L, 1039 Reattempt, 643 Recurrent surgical excision, 872 Registered dietitian nutritionists, 1113 Remnant lipoproteins, 741 Remnants, 784 Renal dysfunction, 173 Residual cardiovascular risk, 409 Residual risk, 741 Resolution, 1047 Retinal vessel analysis, 1523 Reverse cholesterol transport, 99, 137, 849, 1086, 1267 Risk factor, 266 Risk factors, 409, 1346, 1358 Risk prediction, 1493 Risk stratification, 397, 966 Rituximab, 883 Rosuvastatin, 801 S Safety, 277, 835, 1199 Saturated fat, 574 Saturated fatty acids, 455 Scale development, 1225 Screening, 1346 Sebelipase alfa, 604 Secondary dyslipidemia, 1367 Secondary prevention, 1008 Selective peroxisome proliferator-activated receptor a modulator, 1267 Selective PPARa modulator, 173 Sepsis, 822 Serum amyloid A (SAA), 193 Severe hypertriglyceridemia, 243, 1253 Severe xanthomatosis, 872 Sex, 748 Sex steroids, 1072 Sickle cell disease, 1532 Side effects, 1305 Simvastatin, 741 Single-nucleotide polymorphisms, 122 Sitosterolemia, 152, 236, 246, 1164 South Asians, 56 South Korea, 162 Soy, 16 Sphingolipids, 1502, 1513 Spleen, 33 Sri Lanka, 447 Standardization, 300 Statin, 988, 999, 1008, 1027, 1133, 1305 Statin adherence, 711 Statin intolerance, 78, 662 Statin therapy, 972

6 e12 Journal of Clinical Lipidology, Vol 12, No 6, December 2018 Statins, 62, 409, 464, 643, 652, 728, 801, 857, 1371 Stearic acid, 455 Sterol levels, 236 Stratification analyses, 185 Stroke, 928 Sunflower seed oil, 70 Support group, 240 Survey, 367 Sympathetic nervous system, 56 SYNTAX, 1019 T Taiwan, 162 Tangier disease, 1374 Tangier s disease, 878 Task sharing, 626 Task shifting, 626 TG/HDL-C ratio, 734 Therapeutic targets, 45 Therapy, 122 Thermogenic markers, 1421 Time to benefit, 857 Total cholesterol, 383, 588 Treatment gap, 1008 Treatment-related quality of life, 1225 Triglyceride, 185, 211, 321, 437, 810, 1245 Triglyceride-rich lipoproteins, 203 Triglycerides, 99, 173, 254, 311, 356, 506, 588, 773, 1027, 1267, 1371, 1390, 1471, 1493 Tuberous xanthoma, 863 Type 1 hyperlipidemia, 883 Type 1 hyperlipoproteinemia, 305, 908 Type 2 diabetes, 62 Type 2 diabetes mellitus, 45 Type I hyperlipoproteinemia, 920 Type III hyperlipoproteinemia, 1383 U Uncontrolled diabetes mellitus, 305 Urokinase-type plasminogen activator receptor, 203 USRDS, 481 V Variability, 356 Vascular calcification, 767 Vascular disease, 266 Vascular inflammation, 33 Very-low-density lipoprotein, 45 Very low density lipoproteins, 784 Visceral adiposity index, 734 Visit-to-visit variability, 266 Vitamin D, 1305 Vitamin D supplementation, 588 Volanesorsen, 920 Volasenorsen, 254 W Weight reduction, 1113 Whole exome sequencing, 511 Wolman disease, 604 X Xanthoma 243, 868 Xanthomas 152, 1170

Keyword Index to Volume 11

Journal of Clinical Lipidology (2017) 11, e7 e12 Keyword Index to Volume 11 A 7a-hydroxycholesterol, 1032 ABCA1, 242 ABCG5/G8, 1432 Acid sphingomyelinase, 694 Acute ischemic stroke, 915 Acute pancreatitis,